Eledon Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Eledon Pharmaceuticals, Inc. (ELDN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.15M, a 17.07% increase year-over-year.
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.20M, a 23.11% decline year-over-year.
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.43M, a 36.17% increase year-over-year.
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.69M, a 12.05% decline year-over-year.
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.45M, a 20.36% decline from fiscal 2024.
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $13.12M, a 100.49% increase from fiscal 2023.
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.54M, a 19.72% decline from fiscal 2022.
- Eledon Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $8.15M, a 3.15% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.15M 10-Q · filed 2026-08-13 | $5.36M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $2.20M 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $10.45M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $2.43M 10-Q · filed 2025-11-14 | $5.12M derived: sum of 2 quarters · filed 2026-08-13 | $7.99M derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $2.69M 10-Q · filed 2026-08-13 | $5.56M derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $2.86M 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $13.12M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $1.78M 10-Q · filed 2025-11-14 | $4.85M derived: sum of 2 quarters · filed 2025-11-14 | $6.54M derived: sum of 3 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $3.06M 10-Q · filed 2025-11-14 | $4.76M derived: sum of 2 quarters · filed 2025-11-14 | |||
| 2024-03-31 | $1.69M 10-Q · filed 2025-11-14 | ||||
| 2023-12-31 | $6.54M 10-K/A · filed 2025-08-14 | ||||
| 2023-09-30 | $1.73M 10-Q · filed 2024-11-12 | $3.45M derived: sum of 2 quarters · filed 2024-11-12 | $4.83M derived: sum of 3 quarters · filed 2024-11-12 | $6.31M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.72M 10-Q · filed 2024-11-12 | $3.10M derived: sum of 2 quarters · filed 2024-11-12 | $4.58M derived: sum of 3 quarters · filed 2024-11-12 | $6.76M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-03-31 | $1.38M 10-Q · filed 2024-11-12 | $2.85M derived: sum of 2 quarters · filed 2024-11-12 | $5.04M derived: sum of 3 quarters · filed 2024-11-12 | $7.35M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2022-12-31 | $1.47M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-19 | $3.66M derived: sum of 2 quarters · filed 2024-08-19 | $5.97M derived: sum of 3 quarters · filed 2024-08-19 | $8.15M 10-K/A · filed 2024-08-19 | |
| 2022-09-30 | $2.19M 10-Q · filed 2023-11-09 | $4.49M derived: sum of 2 quarters · filed 2023-11-09 | $6.68M 10-Q · filed 2022-11-14 | $8.73M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $2.31M 10-Q · filed 2023-11-09 | $4.49M 10-Q · filed 2022-08-11 | $6.55M derived: sum of 3 quarters · filed 2023-11-09 | $8.59M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-03-31 | $2.19M 10-Q · filed 2023-11-09 | $4.24M derived: sum of 2 quarters · filed 2023-11-09 | $6.28M derived: sum of 3 quarters · filed 2023-11-09 | $8.32M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2021-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.10M derived: sum of 2 quarters · filed 2023-03-30 | $6.13M derived: sum of 3 quarters · filed 2023-03-30 | $7.90M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $2.04M 10-Q · filed 2022-11-14 | $4.08M derived: sum of 2 quarters · filed 2022-11-14 | $5.85M 10-Q · filed 2022-11-14 | $7.51M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $2.03M 10-Q · filed 2022-08-11 | $3.81M 10-Q · filed 2022-08-11 | $5.47M derived: sum of 3 quarters · filed 2022-08-11 | $6.34M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.77M 10-Q · filed 2022-05-12 | $3.43M derived: sum of 2 quarters · filed 2022-05-12 | $4.31M derived: sum of 3 quarters · filed 2022-05-12 | $4.51M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $2.54M derived: sum of 2 quarters · filed 2022-03-24 | $2.73M derived: sum of 3 quarters · filed 2022-03-24 | $3.17M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $878.00K 10-Q · filed 2021-11-12 | $1.07M derived: sum of 2 quarters · filed 2021-11-12 | $1.51M 10-Q · filed 2021-11-12 | $1.75M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $197.00K 10-Q · filed 2021-08-12 | $634.00K 10-Q · filed 2021-08-12 | $877.00K derived: sum of 3 quarters · filed 2021-08-12 | $1.10M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $437.00K 10-Q · filed 2021-05-14 | $680.00K derived: sum of 2 quarters · filed 2021-05-14 | $907.00K derived: sum of 3 quarters · filed 2021-05-14 | $1.53M derived: sum of 4 quarters · filed 2021-05-14 | |
| 2019-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $470.00K derived: sum of 2 quarters · filed 2021-03-31 | $1.10M derived: sum of 3 quarters · filed 2021-03-31 | $1.31M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $227.00K 10-Q · filed 2020-11-16 | $854.00K derived: sum of 2 quarters · filed 2020-11-16 | $1.06M 10-Q · filed 2020-11-16 | $1.81M derived: sum of 4 quarters · filed 2020-11-16 | |
| 2019-06-30 | $627.00K 10-Q · filed 2020-08-14 | $838.00K 10-Q · filed 2020-08-14 | $1.58M derived: sum of 3 quarters · filed 2020-08-14 | $1.82M derived: sum of 4 quarters · filed 2020-08-14 | |
| 2019-03-31 | $211.00K 10-Q · filed 2020-05-15 | $952.00K derived: sum of 2 quarters · filed 2020-05-15 | $1.19M derived: sum of 3 quarters · filed 2020-05-15 | $1.59M derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | $741.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-17 | $978.00K derived: sum of 2 quarters · filed 2020-03-17 | $1.38M derived: sum of 3 quarters · filed 2020-03-17 | $1.54M 10-K · filed 2020-03-17 | |
| 2018-09-30 | $237.00K 10-Q · filed 2019-11-13 | $641.00K derived: sum of 2 quarters · filed 2019-11-13 | $802.00K 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $404.00K 10-Q · filed 2019-08-13 | $565.00K 10-Q · filed 2019-08-13 | |||
| 2018-03-31 | $161.00K 10-Q · filed 2019-05-14 | ||||
| 2017-12-31 | $579.00K 10-K · filed 2019-03-28 | ||||
| 2016-12-31 | $171.00K 10-K · filed 2018-04-02 | $3.00M 10-K · filed 2017-03-03 | |||
| 2015-12-31 | $2.90M 10-K · filed 2017-03-03 | ||||
| 2014-12-31 | $2.11M 10-K · filed 2017-03-03 | ||||
| 2013-12-31 | $238.00K 10-K · filed 2016-03-10 | ||||
| 2012-12-31 | $210.00K 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |